182 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Kris
    Kris
  4. Hyman
    Hyman
  5. Li
    Li
  6. Riely
    Riely
  7. Offin
    Offin
  8. Arcila
    Arcila
  9. Schram
    Schram
  10. Benayed
    Benayed

Groups

  1. Department of Medicine (182)
  2. Solid Tumor Oncology Division (182)
  3. Thoracic Oncology (182)
  4. GSK Faculty (80)
  5. Human Oncology and Pathogenesis Program (68)
  6. Tow Center for Developmental Oncology (TCDO) (57)
  7. Early Drug Development Service (44)
  8. Sloan Kettering Institute Postdocs (44)
  9. Radiology, Department of (38)
  10. Epidemiology and Biostatistics (36)
  1. "Alexander Drilon"
  2. "Solid Tumor Oncology Division"
  3. "Department of Medicine"
  4. "Journal article"
Formats
  1. Journal Article (182)
Groups
  1. Department of Medicine (182)
  2. Solid Tumor Oncology Division (182)
  3. Thoracic Oncology (182)
  4. GSK Faculty (80)
  5. Human Oncology and Pathogenesis Program (68)
  6. Tow Center for Developmental Oncology (TCDO) (57)

More Groups

People
  1. Alexander Drilon (182)
  2. Marc Ladanyi (53)
  3. Maria Arcila (37)
  4. Mark Kris (36)
  5. David Hyman (31)
  6. Bob Li (29)

More People

Years
  1. 2023 (12)
  2. 2022 (30)
  3. 2021 (28)
  4. 2020 (22)
  5. 2019 (23)
  6. 2018 (22)

More Years

Publications
  1. Clinical Cancer Research (26)
  2. JCO Precision Oncology (17)
  3. Journal of Thoracic Oncology (15)
  4. Cancer Discovery (12)
  5. Annals of Oncology (11)
  6. Journal of Clinical Oncology (8)

More Publications

Publishers
  1. American Association for Cancer Research (41)
  2. American Society of Clinical Oncology (26)
  3. Elsevier Inc. (26)
  4. Oxford University Press (15)
  5. Nature Publishing Group (14)
  6. Elsevier Science, Inc. (8)

More Publishers

Results (182)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
    Journal Article

    Rotow, J.; Patel, J. D.; Hanley, M. P.; Yu, H.; Awad, M.; Goldman, J. W.; Nechushtan, H.; Scheffler, M.; Kuo, C. H. S.; Rajappa, S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy
    Journal Article

    Drilon, A.; Sharma, M. R.; Johnson, M. L.; Yap, T. A.; Gadgeel, S.; Nepert, D.; Feng, G.; Reddy, M. B.; Harney, A. S.; Elsayed, M.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Mitogen-activated pathway kinase (MAPK) inhibitor-associated retinopathy: Do features differ with upstream versus down-stream inhibition?
    Journal Article

    Francis, J. H.; Foulsham, W.; Canestraro, J.; Harding, J. J.; Diamond, E. L.; Drilon, A.; Abramson, D. H.
    Ocular Oncology and Pathology (2023)

    Fulltext@MSK | Save
  • A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
    Journal Article

    Repetto, M.; Crimini, E.; Belli, C.; Boscolo Bielo, L.; Ascione, L.; Meric-Bernstam, F.; Drilon, A.; Curigliano, G.
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
    Journal Article

    Goldman, J. W.; Sholl, L. M.; Dacic, S.; Fishbein, M. C.; Murciano-Goroff, Y. R.; Rajaram, R.; Szymczak, S.; Szpurka, A. M.; Chao, B. H.; Drilon, A.
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib
    Journal Article

    Murciano-Goroff, Y. R.; Falcon, C. J.; Lin, S. T.; Chacko, C.; Grimaldi, G.; Liu, D.; Wilhelm, C.; Iasonos, A.; Drilon, A.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics
    Journal Article

    Polk, J. B.; Campbell, J.; Drilon, A. E.; Keating, P.; Cambrosio, A.
    Social Science and Medicine (2023)

    Fulltext@MSK | Save
  • NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations
    Journal Article

    Drilon, A.; Horan, J. C.; Tangpeerachaikul, A.; Besse, B.; Ou, S. H. I.; Gadgeel, S. M.; Camidge, D. R.; van der Wekken, A. J.; Nguyen-Phuong, L.; Acker, A.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Characterization of central nervous system clinico-genomic outcomes in ALK-positive non-small cell lung cancer patients with brain metastases treated with alectinib
    Journal Article

    Miao, E.; Eichholz, J. E.; Lebow, E. S.; Flynn, J.; Zhang, Z.; Walch, H.; Hubbeling, H.; Beal, K.; Moss, N. S.; Yu, K. K.; more...
    Lung Cancer (2023)

    Fulltext@MSK | Save